PAHC

Phibro Animal Health Corp

Add to Watchlist

Advanced Chart

28.550

+0.45(1.601%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

28.780

Open

28.100

VWAP

28.22

Vol

327.57K

Mkt Cap

1.16B

Low

27.830

Amount

9.24M

EV/EBITDA(TTM)

10.79

Total Shares

40.50M

1.80B

EV/OCF(TTM)

20.58

P/S(TTM)

0.96

Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

0.00

-100%

0.600

+11.11%

0.00

-100%

0.670

+91.43%

362.24M

+32.59%

0.521

+27.14%

Estimates Revision

The market is revising No Change the revenue expectations for Phibro Animal Health Corporation (PAHC) for FY2025, with the revenue forecasts being adjusted by -0% over the past three months. During the same period, the stock price has changed by 16.53%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+16.53%

In Past 3 Month

4 Analyst Rating

-8.93% Downside

Wall Street analysts forecast PAHC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAHC is 26.00 USD with a low forecast of 19.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

1 Sell

Hold

-8.93% Downside

Current: 28.550

Low

19.00

Averages

26.00

High

35.00

-8.93% Downside

Current: 28.550

Low

19.00

Averages

26.00

High

35.00

JPMorgan

Ekaterina Knyazkova

Neutral -> Overweight

upgrade

$25 -> $35

2025-07-07

Reason

JPMorgan

Ekaterina Knyazkova

Price Target

$25 -> $35

2025-07-07

upgrade

Neutral -> Overweight

Reason

JPMorgan analyst Ekaterina Knyazkova upgraded Phibro Animal Health to Overweight from Neutral with a price target of $35, up from $25. The firm says the company continues to deliver strong results while the integration of the Zoetis medicated feed additive business is exceeding expectations. Solid animal health portfolio trends should continue, supported by strong customer demand and healthy industry fundamentals, the analyst tells investors in a research note. JPMorgan sees a favorable setup from here.

Morgan Stanley

Equal Weight

maintain

$21 -> $26

2025-06-25

Reason

Morgan Stanley

Price Target

$21 -> $26

2025-06-25

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Phibro Animal Health to $26 from $21 and keeps an Equal Weight rating on the shares. The firm updated its model and price target as its "conviction grows" on better Zoetis MFA portfolio deal integration, the analyst tells investors. A potential inflection in the cattle herd cycle in coming years could also be a tailwind with now greater exposure to the species category, the firm added.

BNP Paribas Exane

Navann Ty

Underperform -> Neutral

upgrade

$24

2025-06-17

Reason

BNP Paribas Exane

Navann Ty

Price Target

$24

2025-06-17

upgrade

Underperform -> Neutral

Reason

BNP Paribas Exane analyst Navann Ty upgraded Phibro Animal Health to Neutral from Underperform with a $24 price target.

Morgan Stanley

Equal Weight

maintain

$20 -> $21

2025-05-08

Reason

Morgan Stanley

Price Target

$20 -> $21

2025-05-08

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Phibro Animal Health to $21 from $20 and keeps an Equal Weight rating on the shares. The "broad-based beat" in fiscal Q3 and guidance raise "should lift the shares," the analyst tells investors in a post-earnings note.

Barclays

Balaji Prasad

Sell

Maintains

$20 → $22

2025-02-10

Reason

Barclays

Balaji Prasad

Price Target

$20 → $22

2025-02-10

Maintains

Sell

Reason

Barclays raised the firm's price target on Phibro Animal Health to $22 from $20 and keeps an Underweight rating on the shares following the fiscal Q2 beat. The company's increased 2025 outlook includes the new MFA portfolio, the analyst tells investors in a research note.

Morgan Stanley

Erin Wright

Hold

Maintains

$20 → $25

2024-12-17

Reason

Morgan Stanley

Erin Wright

Price Target

$20 → $25

2024-12-17

Maintains

Hold

Reason

Morgan Stanley analyst Erin Wright raised the firm's price target on Phibro Animal Health to $25 from $20 and keeps an Equal Weight rating on the shares. Diversified Managed Care "woefully underperformed" in 2024 and while uncertainty is pressuring sentiment, the firm sees "opportunities in a friendlier policy backdrop," the analyst tells investors in a 2025 outlook note on the healthcare services group.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Phibro Animal Health Corp (PAHC.O) is 11.65, compared to its 5-year average forward P/E of 13.78. For a more detailed relative valuation and DCF analysis to assess Phibro Animal Health Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

13.78

Current PE

11.65

Overvalued PE

16.95

Undervalued PE

10.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

9.17

Current EV/EBITDA

8.54

Overvalued EV/EBITDA

10.80

Undervalued EV/EBITDA

7.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

0.76

Current PS

0.79

Overvalued PS

0.99

Undervalued PS

0.54